Literature DB >> 21385769

Changes in renal vessels following the long-term administration of an angiotensin II receptor blocker in Zucker fatty rats.

Kazushige Nakanishi1, Yohko Nagai, Tatsuo Akimoto, Hirohito Kato, Nadezhda Yanakieva-Georgieva, Yukio Ishikawa, Kastunori Yoshihara, Kinji Ito, Nobuaki Yamanaka, Takashi Oite.   

Abstract

INTRODUCTION: The nephro-protective effects of angiotensin II receptor blockers (ARBs) are widely known; however, there are few reports of long-term effects focusing on the renal vessels. We studied afferent arteriolar changes induced by the long-term administration of an ARB.
MATERIALS AND METHODS: Thirty-two 6-week-old male Zucker fatty rats (ZFRs) were divided into following four groups (n = 8 in each): ZFR Group and ZFR+High Group fed a standard or high-salt diet, respectively; ZFR+ARB Group and ZFR+High+ARB Group fed a standard or high-salt diet with ARB (Olmesartan, 5 mg/kg/day), respectively. Blood pressure, proteinuria, morphological examinations and glomerular haemodynamics in vivo were studied.
RESULTS: Marked proliferative changes in the afferent arteriolar smooth muscle cells (SMCs) were frequently observed in the two groups given ARBs; in the ZFR+ARB group (77.3±10.3%) compared with the two groups without ARB (1.7%, p < 0.005; 1.2%, p < 0.0005) and 37.4±15.6% in the ZFR+High+ARB group. Proteinuria markedly decreased in the groups treated with ARBs, but the glomerular erythrocyte velocities showed no differences.
CONCLUSIONS: Our findings indicate that long-term ARB administration induced unusual proliferative changes in SMCs of afferent arterioles of ZFRs. These changes could narrow arteriolar lumens and reduce intraglomerular pressure, but they could cause also irreversible damage to the arterioles.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385769     DOI: 10.1177/1470320310387844

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  6 in total

1.  Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.

Authors:  Swayam Prakash Srivastava; Julie E Goodwin; Keizo Kanasaki; Daisuke Koya
Journal:  Br J Pharmacol       Date:  2020-06-22       Impact factor: 8.739

Review 2.  Renin-angiotensin system in the kidney: What is new?

Authors:  Fernanda M Ferrão; Lucienne S Lara; Jennifer Lowe
Journal:  World J Nephrol       Date:  2014-08-06

3.  Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.

Authors:  Hiroyuki Daikuhara; Kensaku Fukunaga; Tomie Ohshima
Journal:  Drug Des Devel Ther       Date:  2014-02-17       Impact factor: 4.162

4.  Prominent hyperplasia of renin-producing juxtaglomerular apparatus after chronic and complete blockade of the renin-angiotensin system in adult IgA nephropathy.

Authors:  Michiaki Abe; Kensuke Joh; Norio Ieiri; Osamu Hotta; Yasunori Utsunomiya; Hiroshi Sato; Kiyomi Kisu; Naoki Sakumo; Hideyasu Kiyomoto; Toshinobu Sato; Yoshio Taguma; Sadayoshi Ito
Journal:  CEN Case Rep       Date:  2015-04-09

5.  Changes in renal vessels associated with long-term administration of angiotensin converting enzyme inhibitor in Zucker fatty rats.

Authors:  Kazushige Nakanishi; Yohko Nagai; Tatsuo Akimoto; Nobuaki Yamanaka
Journal:  J Smooth Muscle Res       Date:  2017

Review 6.  Renin Cells, the Kidney, and Hypertension.

Authors:  Maria Luisa S Sequeira-Lopez; R Ariel Gomez
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.